Mendus
Clinical-stage company developing immunotherapies to prevent tumor recurrence.
IMMU | ST
Overview
Corporate Details
- ISIN(s):
- SE0005003654 (+1 more)
- LEI:
- 529900AFBGFR7ZB50J95
- Country:
- Sweden
- Address:
- Västra Trädgårdsgatan 15, 111 53 Stockholm
- Website:
- https://mendus.com/
- Sector:
- Manufacturing
Description
Mendus is a clinical-stage company developing immunotherapies to improve long-term survival for cancer patients. The company's primary focus is on preventing tumor recurrence, a leading cause of cancer-related mortality. By leveraging its expertise in allogeneic dendritic cell biology, Mendus designs therapies that stimulate the immune system to build active and long-lasting immunity against residual cancer cells. This approach aims to change the course of cancer treatment by offering durable responses while preserving the patient's quality of life. The company's pipeline is centered on maintenance therapies for various forms of cancer.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2018-10-19 08:00 |
Immunicum AB (publ) Announces Nomination Committee for AGM 2019
|
English | PDF • 59.2 KB | ||
| 2018-10-18 13:14 | English | PDF • 35.3 KB | |||
| 2018-10-16 16:45 |
Immunicum AB (publ) förtydligar information kring riktad emission
|
Swedish | PDF • 80.9 KB | ||
| 2018-10-16 16:45 |
Immunicum AB (publ) Clarifies Information Regarding Directed Issue
|
English | PDF • 93.6 KB | ||
| 2018-10-01 16:01 |
Immunicum AB (publ) lämnar information med anledning av handelsstopp och pågåen…
|
Swedish | PDF • 65.4 KB | ||
| 2018-10-01 16:01 |
Immunicum AB (publ) Gives Information on Trading Halt and Ongoing Negotiations …
|
English | PDF • 65.0 KB | ||
| 2018-08-17 08:01 | Swedish | PDF • 690.9 KB | |||
| 2018-08-17 08:01 | English | PDF • 635.7 KB | |||
| 2018-07-23 08:01 |
Immunicum AB (publ) meddelar att FDA godkänt protokollet som möjliggör starten …
|
Swedish | PDF • 77.8 KB | ||
| 2018-07-23 08:01 |
Immunicum AB (publ) Announces Protocol Approval by the FDA Enabling the Initiat…
|
English | PDF • 77.3 KB | ||
| 2018-07-11 13:32 | English | PDF • 35.4 KB | |||
| 2018-07-10 13:05 | English | PDF • 35.4 KB | |||
| 2018-05-30 14:37 | English | PDF • 35.4 KB | |||
| 2018-05-22 13:55 | English | PDF • 35.4 KB | |||
| 2018-05-21 08:01 |
Immunicum AB (publ) Announces End of Enrollment in Phase I/II GIST Clinical Tri…
|
English | PDF • 70.7 KB |
Automate Your Workflow. Get a real-time feed of all Mendus filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Mendus
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Mendus via our API.
Peer Companies
